Application
It’s suggested that ST1326, in treating chronic lymphocytic leukemia (CLL) cells, is a promising addition to anti-CLL drug combinations, targeting leukemia cell activation and proliferation. ST1326 displays significant potential to enhance current CLL therapies, even in cases where drugs lose efficacy on proliferating cells. Notably, it is effective at lower concentrations than common inhibitors and synergizes with ABT-199 and fludarabine.
ST1326 can effectively inhibit FAO (fatty acid oxidation), which leukemia cell lines need for survival. It does this by selectively targeting the CPT1A isoform and inducing mitochondrial dysfunction, triggering the mitochondrial apoptotic pathway. With this action, ST1326 achieves antitumor activity by leading to apoptosis induction in leukemia cell metabolism while sparing normal bone marrow progenitors. Data gathered on primary hematopoietic malignant cells confirmed the FAO inhibition and cytotoxic activity of ST1326, particularly on acute myeloid leukemia cells.
